Natural Alternatives International vs Zevra Therapeutics
Natural Alternatives International is the larger business, with $143m of revenue in fiscal 2026 against $106m for Zevra Therapeutics (1.3 times as much). Zevra Therapeutics grew faster (350.9% against 9.7%). Zevra Therapeutics kept more of each dollar of sales as profit: a net margin of 78.2% against -14.5%.
| Latest fiscal year | Natural Alternatives InternationalNAII, 2026 | Zevra TherapeuticsZVRA, 2025 |
|---|---|---|
| Revenue | $143m | $106m |
| Revenue growth | 9.7% | 350.9% |
| Net income | −$20.7m | $83.2m |
| Operating margin | — | -59.1% |
| Net margin | -14.5% | 78.2% |
| Return on equity | -35.0% | 85.7% |
| Free cash flow | −$12.6m | −$2.4m |
| Cash | $7.4m | $62.4m |
| Total debt | $18.0m | $63.6m |
| Debt to equity | — | 41.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $89,000 | — |
| Employees | 219 | 61 |
| Market value | $6.7m | $604m |
| Price vs our value range | — | — |
| Moat score | 27 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 14 buys, 0 sales | 0 buys, 13 sales |